SCYXNasdaq

SCYNEXIS INC

Alert me on SCYX

Insider buys, 6 months

Congress trades, 6 months

Signals, 6 months

Six months

After each filing

No purchase or sale on this ticker by a member of Congress or an insider yet.

Filings for SCYX

27 held · newest 527 held · newest 2

Loading the filings.

See all 27 filings for SCYX

Aeon news and offers by email

New sources, new features and offers like our founding price. A few times a month at most. Stop any time.

Signal history

No signal for this ticker yet. A signal is written when insider buying here scores one dot or more.

Stakes

Jun 30, 2026 Schedule 13G, amended

CVI Investments, Inc.: 5.9%, 615,522 shares

Jun 30, 2026 Schedule 13G, amended

Great Point Partners, LLC: 10%, 4,076,068 shares

Jun 30, 2026 Schedule 13G

Adage Capital Management, L.P.: 10%, 1,041,824 shares

Jun 30, 2026 Schedule 13G, amended

Federated Hermes, Inc.: 4%, 441,658 shares

Jun 30, 2026 Schedule 13G, amended

Federated Hermes, Inc.: 4.5%, 55,207 shares

Mar 31, 2026 Schedule 13G, amended

CVI Investments, Inc.: 6.2%, 3,956,319 shares

Sep 9, 2025 Schedule 13G

CVI Investments, Inc.: 6.7%, 3,008,874 shares

Mar 31, 2026 Schedule 13G

Squadron Master Fund LP: 9.6%, 7,608,695 shares

Mar 31, 2026 Schedule 13G

Great Point Partners, LLC: 10%, 7,978,713 shares

Dec 31, 2025 Schedule 13G, amended

Avidity Partners Management LP: 9.9%, 4,426,565 shares

Dec 31, 2025 Schedule 13G, amended

KINGDON CAPITAL MANAGEMENT, L.L.C.: 0%, 0 shares

Dec 31, 2025 Schedule 13G, amended

Federated Hermes, Inc.: 8.4%, 3,533,250 shares

Sep 30, 2025 Schedule 13G, amended

Avidity Partners Management LP: 9.9%, 4,281,284 shares

Sep 30, 2025 Schedule 13G, amended

Kingdon Capital Management, L.L.C.: 5.3%, 2,237,048 shares

Sep 30, 2025 Schedule 13G, amended

Federated Hermes, Inc.: 11.3%, 5,116,598 shares

Schedule 13D is filed within 5 business days of crossing 5 percent by an investor who may seek to influence the company. Schedule 13G is filed by a passive holder, and a large institution has up to 45 days after the quarter end.

Government contracts, last 12 months

Awards of $10M and up, from USAspending · context, not a signal

Sep 25, 2026 Office of Assistant Secretary for Preparedness and Response $18.5M ADVANCE THE DEVELOPMENT OF SCY-247, A NOVEL ANTIFUNGAL CURRENTLY IN PHASE 1 CLINICAL TRIALS, FOR THE TREATMENT OF INVASIVE CANDIDIASIS AND PROPHYLAXIS OF INVASIVE FUNGAL DISEASE AS ORAL AND IC FORMULA

1 award, $18.5M in the last 12 monthsOriginal awards ↗

Lobbying

Last four quarters

No lobbying reports on file.